Market News & Trends
ALS Therapy Development Institute & to-BBB Collaborate on Motor Neuron Disease
The ALS Therapy Development Institute (ALS TDI) recently announced it has entered into a new collaboration with to-BBB to investigate potential treatments for ALS…
Aptuit & Aegerion Sign Long-Term API Agreement
Stuart Needleman, President and Chief Operating Officer, Aptuit LLC, recently announced that Aptuit and Aegerion Pharmaceuticals, Cambridge, MA, have signed a long-term supply agreement…
BIND Biosciences & Amgen Sign Worldwide Development & Commercialization Agreement
BIND Biosciences recently announced it has entered into a global collaboration agreement with Amgen Inc. to develop and commercialize a kinase inhibitor nanomedicine for…
Catalent Makes Major Inhalation Capabilities Investment
Catalent Pharma Solutions recently announced it will make a major investment to expand its industry-leading inhalation drug development, delivery, and supply capabilities by enhancing…
Novozymes Biopharma Aligns Recombinant Human Albumin Portfolio
Novozymes Biopharma recently announced the introduction of a new brand and visual identity for its recombinant human albumin (rAlbumin) portfolio. As part of the…
UPM Pharmaceuticals Enhances Pre-Formulation Capabilities
UPM Pharmaceuticals recently announced it has purchased and qualified a TA Instruments Q20 Auto MDSC (Differential Scanning Calorimeter), and a TA Instruments Q50 TGA…
1/9/2013
Ultragenyx Secures $75 Million for Ultra-Rare Diseases Ultragenyx Pharmaceutical Inc. recently announced the successful completion of a $75-million Series B round financing led by Adage…
goBalto Secures Additional Funding for Web-Based Clinical Study Platform
 goBalto, Inc. recently announced it closed a $12 million round of venture financing, led by EDBI, the global investment arm of Singapore's Economic Development…
Halozyme Therapeutics Enters Lucrative Agreement With Pfizer
 Halozyme Therapeutics, Inc. recently announced it has entered into a worldwide collaboration and license agreement with Pfizer Inc. for the purpose of developing and…
Independent AbbVie Officially Launches
 AbbVie recently marked its launch as an independent biopharmaceutical company, with employees from more than 40 countries and patients joining AbbVie leaders as they…
Infinity Pharmaceuticals Pays Millennium $15 Million
 Infinity Pharmaceuticals, Inc. recently announced that the company amended its development and license agreement with Millennium: The Takeda Oncology Company and Takeda Pharmaceutical Company…
Perrigo Acquires Remaining Stake in Drug Development Company for Nearly $45 Million
 Perrigo Company recently announced it has signed a definitive merger agreement and has completed the acquisition of Cobrek Pharmaceuticals, Inc. (Cobrek), a privately held,…
Ultragenyx Secures $75 Million for Ultra-Rare Diseases
 Ultragenyx Pharmaceutical Inc. recently announced the successful completion of a $75-million Series B round financing led by Adage Capital Partners, LP. Joining Adage as…
12/27/2012
Radius & 3M Announce Exclusive Agreement Radius Health, Inc. and 3M Drug Delivery Systems recently announced an exclusive partnership agreement for development and commercialization of…
Aptuit & Alios BioPharma to Collaborate
 Stuart Needleman, President and Chief Operating Officer, Aptuit LLC, recently announced that Aptuit and Alios BioPharma, South San Francisco, California, are collaborating in lead…
Atlantic Pharmaceuticals Makes Major Announcement
 Atlantic Pharmaceuticals, Inc. recently announced that new patents have been issued by the USPTO relating to its tamper-resistant SMART/Script drug delivery platform. US Patent…
Blend Therapeutics Secures $16 Million
 Blend Therapeutics, Inc. recently announced it has secured a $16-million Series B financing. Blend is pioneering an integrative model for discovering novel molecular entities…
Pisgah Laboratories Receives Patent for Abuse-Deterrent Technology
 Pisgah Laboratories, Inc. recently announced it has received US Patent No. 8,334,322 from the United States Patent and Trademark Office for innovative, abuse-deterrent forms…
Radius & 3M Announce Exclusive Agreement
 Radius Health, Inc. and 3M Drug Delivery Systems recently announced an exclusive partnership agreement for development and commercialization of BA058-transdermal (TD). BA058 is a…
Raptor Signs $50-Million Agreement With HealthCare Royalty Partners
 Raptor Pharmaceutical Corp. recently announced it has signed a $50-million loan agreement with HealthCare Royalty Partners to help fund the commercialization of PROCYSBI, the…
